A post-marketing survey evaluating the safety and efficacy of a fixed-dose single-pill combination of cilnidipine and valsartan in patients with hypertensio
Not Applicable
- Conditions
- Hypertension
- Registration Number
- JPRN-UMIN000037536
- Lead Sponsor
- EA Pharma Co., Ltd. Post-Marketing Medical Research Group, Medical Dept.
- Brief Summary
Data were collected for 2095 patients. A total of 2045 patients met the criteria of this surveillance protocol. Among these patients, 53.6% were male, 46.4% were female, and the average age was 67.5 years. Seventy two cases (3.52%) of adverse drug reactions were observed. Systolic blood pressure, diastolic blood pressure, and pulse rate, measured either at office or at home, decreased significantly after 3 months, and this effect was maintained for 12 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2622
Inclusion Criteria
Not provided
Exclusion Criteria
1) Violation of registration criteria 2) Lost to follow up after initial visit 3) Not administered
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method